Literature DB >> 19030376

Is montelukast effective and well tolerated in the management of asthma in young children?: Part B: Clinical commentary.

Michael Bh Smith1.   

Abstract

Entities:  

Year:  2007        PMID： 19030376      PMCID： PMC2528683          DOI： 10.1093/pch/12.4.309

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  10 in total

1.  British guideline on the management of asthma.

Authors: 
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

2.  Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data.

Authors:  Craig Jones; Nancy C Santanello; Steve J Boccuzzi; Jenifer Wogen; Peg Strub; Linda M Nelsen
Journal:  J Asthma       Date:  2003-02       Impact factor: 2.515

3.  Short-course montelukast for intermittent asthma in children: a randomized controlled trial.

Authors:  Colin F Robertson; David Price; Richard Henry; Craig Mellis; Nicholas Glasgow; Dominic Fitzgerald; Amanda J Lee; Jane Turner; Melissa Sant
Journal:  Am J Respir Crit Care Med       Date:  2006-11-16       Impact factor: 21.405

4.  Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma.

Authors:  Janet van Adelsberg; James Moy; Lynn X Wei; Carol A Tozzi; Barbara Knorr; Theodore F Reiss
Journal:  Curr Med Res Opin       Date:  2005-06       Impact factor: 2.580

5.  Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy.

Authors:  J F Maspero; E Dueñas-Meza; B Volovitz; C Pinacho Daza; L Kosa; F Vrijens; J A Leff
Journal:  Curr Med Res Opin       Date:  2001       Impact factor: 2.580

Review 6.  Leukotriene modifiers in pediatric asthma management.

Authors:  H Bisgaard
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

7.  Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Authors:  B Knorr; L M Franchi; H Bisgaard; J H Vermeulen; P LeSouef; N Santanello; T M Michele; T F Reiss; H H Nguyen; D L Bratton
Journal:  Pediatrics       Date:  2001-09       Impact factor: 7.124

Review 8.  Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

Authors:  F M Ducharme; G C Hicks
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.

Authors:  J van Adelsberg; G Philip; A J Pedinoff; E O Meltzer; P H Ratner; J Menten; T F Reiss
Journal:  Allergy       Date:  2003-12       Impact factor: 13.146

10.  Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.

Authors:  Hans Bisgaard; Stefen Zielen; María Luz Garcia-Garcia; Sebastian L Johnston; Leen Gilles; Joris Menten; Carol A Tozzi; Peter Polos
Journal:  Am J Respir Crit Care Med       Date:  2004-11-12       Impact factor: 21.405
  10 in total
  1 in total

1.  Effects of Montelukast on free radical production in whole blood and isolated human polymorphonuclear neutrophils (PMNs) in asthmatic children.

Authors:  Muslim M Al Saadi; Sultan Ayoub Meo; Ali Mustafa; Ahmed Shafi; Ali S Al Tuwajri
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.